RUHS Insulin Conclave- Insulin: Past, Present & Future

Oral to Injectable – When, Why & How
Therapeutic inertia to Insulin therapy - Magnitude of problem & solution
Individualization of Insulin therapy for T2DM in Indian scenario
Relevance of premix analogue insulin's in the dynamic era of newer insulin's
Panel Discussion and Q&A All Faculty Summary & Wrap up

1. RUHS INSULIN CONCLAVE DR. SUDHIR BHANDARI MD, DNB, MNAMS, FRCP (London), FRCP (Edinburgh) FELLOW AMERICAN COLLEGE OF ENDOCRINOLOGY (FACE) FELLOW AMERICAN COLLEGE OF PHYSICIANS (FACP) FELLOW INDIAN COLLEGE OF PHYSICIANS (FICP) FLLOW RESEARCH SOCIETY FOR THE STUDY OF DIABETES IN INDIA (FRSSDI) Senior Professor of Medicine Consultant-Internal Medicine, Diabetes & Endocrinology HON. PHYSICIAN TO H.E.THE GOVERNOR OF RAJASTHAN Vice Chancellor – Rajasthan University of Health Science, Rajasthan

2. RUHS INSULIN CONCLAVE Century B iggest Discovery Insulin therapy: Before v/s After

3. Insulin: Past, Present & Future

4. History of Diabetes and Insulin

5. Etiopathologenesis of Diabetes

6. Incidence and Risk of Diabetes

7. S. No. Characteristics In World In India USA 1 Total Diabetic patients 460 million 80 million 30 million 2 On OHA   89% 69% 3 On Insulin   11% 31% 4 Good Controlled DM   36%   5 Insulin initiation time     4.5 years 6 Average life expectancy (Years) 74.1 year 70.96 74.6

8. Oral to Injectable – When, Why & How Dr. Shashank R Joshi Glycaemic control in India is far from ideal with a mean HbA 1c of 9.0%, which is at least 2.0% higher than global standards 2 Most common reason behind this is that Indians always delays in adding new treatment and this is combined with late diagnosis and late treatment initiation.

9. 2. Therapeutic inertia to Insulin therapy - Magnitude of problem & solution Dr. Sanjay Agarwal In recently published ICMR-INDIAB-13 Study Only 11·1% (10·1–12·1) of Diabetic Indians were on insulin In India approximately 80 million individuals have Diabetes. Out of these only 60% patients on medications and only 11% patients on insulin. Prolonged periods of uncontrolled hyperglycemia leads to Increased risk of diabetes complications & CV Mortality

10. 3. Individualization of Insulin therapy for T2DM in Indian scenario Dr. Kamalakar Tripathi Glycaemic control in India is far from ideal with a mean HbA 1c of 9.0%, which is at least 2.0% higher than global standards 2 How type 2 Diabetes can change over Time management for Diabetes

11. 4 . Relevance of premix analog insulin in the dynamic era of newer insulin Dr. Sunil Gupta There is a pharmacoeconomic advantage of insulin analogs due to improved glycemic control, improved adherence to therapy (less fear of hypoglycemia and weight gain), and lower rates of hypoglycemia

12. RUHS INSULIN CONCLAVE Oral to Injectable – When, Why & How Therapeutic inertia to Insulin therapy - Magnitude of problem & solution Individualization of Insulin therapy for T2DM in Indian scenario Relevance of premix analogue insulin's in the dynamic era of newer insulin's Panel Discussion and Q&A All Faculty Summary & Wrap up